Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Tuberculosis

Free Subscription 22.12.2025 1 Eur J Clin Microbiol Infect Dis 1 Eur Respir J 6 Int J Tuberc Lung Dis 1 J Antimicrob Chemother 1 Lancet 1 N Engl J Med 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Eur J Clin Microbiol Infect Dis

1. ROTUNDO S, Serapide F, Guido G, Di Gennaro F, et al
   Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees.
   Eur J Clin Microbiol Infect Dis. 2025 Dec 16. doi: 10.1007/s10096-025-05304.
   PubMed        
   
   

   
   Eur Respir J

2. BERANGER A, Solans BP, Miyakawa R, McIlleron H, et al
   Efficacy of isoniazid in pediatric tuberculosis: an individual participant data meta-analysis.
   Eur Respir J. 2025 Dec 18:2501046. doi: 10.1183/13993003.01046-2025.
   PubMed         Abstract available
   
   

   
   Int J Tuberc Lung Dis

3. HARRIES AD, Kumar AMV, Nair D, Satyanarayana S, et al
   Operational research to End TB: 2(nd) edition of the Union's Guide to operational research.
   Int J Tuberc Lung Dis. 2025;29:431-433.
   PubMed         Abstract available
   
   
4. CASTELLINO LM, Nguyen S, Cobb S, Sreeramoju PV, et al
   Identifying MTB-exposed homeless persons with an electronic health record alert: a safety-net health system's experience.
   Int J Tuberc Lung Dis. 2025;29:441-446.
   PubMed         Abstract available
   
   
5. SHARMA S, Patankar S, Becerra MC, Bhalla M, et al
   Yield of a contact investigation among children living with drug-resistant TB patients.
   Int J Tuberc Lung Dis. 2025;29:455-461.
   PubMed         Abstract available
   
   
6. PERUMAL R, Pillay S, Bagratee N, Tulsi J, et al
   Anatomical and functional characteristics of symptomatic post-TB lung disease.
   Int J Tuberc Lung Dis. 2025;29:434-440.
   PubMed         Abstract available
   
   
7. SINGH S, Boorgula GD, Galvez RA, Heysell SK, et al
   Mycobacteria susceptibility to epetraborole: how far can it go?
   Int J Tuberc Lung Dis. 2025;29:447-454.
   PubMed         Abstract available
   
   
8. KODAMA T, Sasaki Y, Tsuyuguchi K, Okumura M, et al
   Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB.
   Int J Tuberc Lung Dis. 2025;29:462-468.
   PubMed         Abstract available
   
   

   
   J Antimicrob Chemother

9. UEAPHONGSUKKIT T, Udomkarnjananun S, Vanichanan J, Jutivorakool K, et al
   Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients.
   J Antimicrob Chemother. 2025 Dec 16:dkaf439. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Lancet

10. HUI D, Sahu S, Ditiu L, Marais BJ, et al
    Global tuberculosis response off track: urgent priorities to end the world's top infectious killer.
    Lancet. 2025 Dec 11:S0140-6736(25)02433-X. doi: 10.1016/S0140-6736(25)02433.
    PubMed        
    
    

    
    N Engl J Med

11. MEYA DB, Cresswell FV, Dai B, Engen N, et al
    Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
    N Engl J Med. 2025;393:2434-2446.
    PubMed         Abstract available
    
    

    
    PLoS One

12. DANSO EK, Asare P, Tetteh AY, Tetteh P, et al
    Mycobacterium tuberculosis complex lineages and drug resistance patterns among tuberculosis patients with or without diabetes mellitus in southern Ghana.
    PLoS One. 2025;20:e0338498.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.